Please use this identifier to cite or link to this item:
|Title:||Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration|
|Source:||Farooqui, A.A.,Ong, W.-Y.,Horrocks, L.A. (2004-03). Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration. Current Drug Targets - Cardiovascular and Haematological Disorders 4 (1) : 85-96. ScholarBank@NUS Repository. https://doi.org/10.2174/1568006043481239|
|Abstract:||Phospholipases A2 (PLA2) belong to a super-family of enzymes that hydrolyze membrane phospholipids at the sn-2 position to liberate free fatty acids and lysophospholipids. Different forms of PLA 2 are involved in inflammation, neurodegeneration, and intracellular and intercellular signaling related to neurotransmitter release, axonal growth and gene expression. The action of cytosolic PLA 2 (cPLA2) on phospholipid containing arachidonic acid at the sn-2 position releases arachidonic acid and lysophospholipids, precursors for various proinflammatory lipid mediators including prostaglandins, leukotrienes, thromboxanes, and platelet activating factor. During hypoxic/ischemic insults, alterations in calcium homeostasis and induction of cytokines results in stimulation of cPLA2 and increased production of prostaglandins, leukotrienes, thromboxanes, and platelet activating factor. These metabolites cause atherosclerotic plaque development in cerebrovascular and coronary artery diseases in arterial walls and neuronal cell injury in brain tissue. Our studies on kainic acid-induced neurodegeneration in rat brain indicate that the stimulation of cPLA2 increased generation of proinflammatory lipid mediators, and accumulation of 4-hydroxynonenal, a toxic aldehyde with neurodegenerative properties. Treatment of rat brain hippocampal slices with antimalarial drugs (non-specific cPLA2 inhibitors), arachidonyl trifluoromethyl ketone (a specific cPLA2 inhibitor), or surfactin (a non-specific cPLA2 inhibitor) not only inhibits cPLA 2 activity but also blocks neurodegeneration suggesting that cPLA2 inhibitors can be used as neuroprotective and anti-inflammatory agents in neurodegenerative diseases. © 2004 Bentham Science Publishers Ltd.|
|Source Title:||Current Drug Targets - Cardiovascular and Haematological Disorders|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 20, 2018
checked on Feb 16, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.